ExpreS2ion Biotechnologies (EXPRS2.ST) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

ExpreS2ion Biotechnologies is a clinical-stage biotech focused on developing transformative vaccines using its proprietary ExpreS2 protein expression platform. Founded in 2010 and publicly listed on Nasdaq First North Growth Market Sweden, the company has advanced its lead HER2-targeted cancer vaccine, ES2B-C001, into Phase 1 trials, demonstrating promising early immunogenicity. Its strategy leverages the ExpreS2 platform's ability to efficiently produce properly folded antigens to build a pipeline targeting high-need areas in oncology and infectious diseases.

OncologyInfectious Diseases

Technology Platform

Proprietary ExpreS2 protein expression system based on Drosophila S2 insect cells, enabling high-yield production of complex, properly folded and glycosylated recombinant antigens for vaccine development.

Opportunities

The lead HER2 cancer vaccine candidate, ES2B-C001, addresses a multi-billion dollar market with a novel mechanism that could overcome limitations of current antibody therapies.

The versatile ExpreS2 platform also creates opportunities to rapidly develop vaccines for high-need infectious diseases.

Risk Factors

High clinical risk as the lead candidate is only in Phase 1 trials.

The company is pre-revenue and will require significant additional capital, leading to potential shareholder dilution.

It faces intense competition from established HER2 therapies and other vaccine technologies.

Competitive Landscape

Faces competition from approved HER2 monoclonal antibodies and ADCs, as well as other HER2 vaccine developers. Its technology platform competes with other protein expression systems (CHO, baculovirus) and modern mRNA platforms for vaccine antigen production.

More companies in Biologics / Biosimilars →More companies in Denmark →